Prof. Chorev received his Ph.D. from the Hebrew University in 1976 and completed his post-doctoral training in 1979 at the University of California, San Diego. In 1995 he retired from the Hebrew University where he held the Drs. Margaret and Henry Zentner Chair of Pharmaceutical Chemistry. He is currently on the faculty of Harvard Medical School and a member of the Laboratory for Translational Research, Division of Hematology, Department of Medicine at Brigham and Women’s Hospital. He is the co-inventor of Exelon® (Rivastigmine), a prescribed drug for treatment of mild to moderate dementia caused by Alzheimer’s or Parkinson’s disease, and Ladostigil, a drug developed to treat Mild Cognition Impairment. Prof. Chorev is a recipient of the 2013 Vincent du Vigneaud Award from the American Peptide Society. Prof. Chorev served as a member of the Editorial Boards of the Journal of Peptide Research and Biopolymers and is currently an Editor for the Journal of Peptide Science. His research covered a wide range of bioactive peptides and small molecules as molecular probes and drug leads. Together with Prof. Murray Goodman he formulated and developed the concept of the partial retro-inverso modification and methodologies of implementation. He is currently focused on exploring the therapeutic potential of CuAAC-mediated macrocyclization via of side chain-to-side chain in bioactive peptides and is a scientific founder of Mellitus LLC, a start-up dedicated to bring glycated CD59 (GCD59), a novel biomarker of glycemic load, from the bench to the bedside as an advanced in vitro diagnostic.